Table 2. Prevalence of excluded patients from the inclusion & exclusion criteria of EMPEROR-Reduced and EMPEROR-Preserved trial.
| EMPEROR-Reduced & EMPEROR-Preserved criteria | Prevalence | |||
|---|---|---|---|---|
| KorAHF-HFrEF (n = 3,108) | KorAHF-HFpEF (n = 2,070) | KorAHF-Total (n = 5,178) | ||
| No. of patients who unsatisfied the inclusion criteria | ||||
| Age < 18 yr | 0 (0) | 0 (0) | 0 (0) | |
| NYHA class I | 0 (0) | 0 (0) | 0 (0) | |
| Unelevated NT-proBNPa | 440 (14.2) | 616 (29.8) | 1,056 (20.4) | |
| No. of patients who satisfied the exclusion criteria | ||||
| Systolic blood pressure ≥ 180 mmHg or < 100 mmHg | 582 (18.7) | 230 (11.1) | 812 (15.7) | |
| Systolic blood pressure < 100 mmHg | 580 (18.7) | 227 (11.0) | 807 (15.6) | |
| eGFR < 20 mL/min/1.73 m2 or requiring dialysis | 273 (8.8) | 172 (8.4) | 446 (8.6) | |
| Cardiomyopathy (infiltrative, accumulation, reversible cause) | 170 (5.5) | 83 (4.0) | 253 (4.9) | |
| History of acute (< 4 wk) myocardial infarction | 345 (11.1) | 218 (10.5) | 563 (10.9) | |
| A-Fib/A-Flutter with a resting heart rate of > 110 bpm | 26 (0.8) | 25 (1.2) | 51 (1.0) | |
| Active or suspected malignancy | 267 (8.6) | 152 (7.3) | 419 (8.1) | |
| Hemoglobin of < 9 g/dL | 110 (3.5) | 120 (5.8) | 230 (4.4) | |
Values are presented as number (%).
A-Fib = atrial fibrillation, A-Flutter = atrial flutter, eGFR = estimated glomerular filtration rate, EMPEROR-Preserved = EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction, EMPEROR-Reduced = EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction, HFpEF = heart failure with preserved ejection fraction, HFrEF = heart failure with reduced ejection fraction, KorAHF = Korean Acute Heart Failure, LVEF = left ventricular ejection fraction, NT-proBNP = N-terminal prohormone B-type natriuretic peptide, NYHA = New York Heart Association.
a40% < LVEF: NT-proBNP ≤ 300 pg/mL in patients without atrial fibrillation and ≤ 900 pg/mL in patients with atrial fibrillation. 40% ≥ LVEF: NT-proBNP < 600 pg/mL in patients without atrial fibrillation and < 1,200 pg/mL in patients with atrial fibrillation.